Conference Coverage

Don’t shorten therapy for older, sicker cellulitis patients


 

REPORTING FROM ECCMID 2018

After initial treatment, 151 patients entered the randomization phase. At 28 days, relapse-free cure rates were nearly identical: 49% of the 12-day group and 50% of the 6-day group. However, by 90 days, a significant difference became apparent: Patients who had received the 6-day course of flucloxacillin were significantly more likely to have experienced a relapse of cellulitis in the same region (23.5% vs. 6% in the 12-day group). A Kaplan-Meier analysis showed that these patients began to relapse as early as 35 days after the end of therapy. Most relapses occurred during days 60-90. The few relapses in the 12-day group occurred toward the end of the follow-up period, from day 75 onward.

Dr. Cranendonk said the investigation shows that older, less-healthy cellulitis patients can probably benefit from the longer course of antibiotics. “Short-term outcomes aren’t everything,” he noted.

He had no financial disclosures.

A video interview of Dr. Cranendock by ECCMID 2018 is available.

SOURCE: Cranendonk et al. ECCMID 2018, Abstract O1122

Pages

Recommended Reading

FDA bans 24 ingredients from OTC health care antiseptic products
MDedge Family Medicine
Risks identified for drug-resistant bacteremia in cirrhosis
MDedge Family Medicine
Common food additive makes C. difficile more virulent
MDedge Family Medicine
Antibiotic choice for acute otitis media 2018
MDedge Family Medicine
Drug combo indicated for bacterial pneumonia
MDedge Family Medicine
Reported penicillin allergies hike inpatient costs
MDedge Family Medicine
FDA warns against clarithromycin use in patients with heart disease
MDedge Family Medicine
QI initiative reduces antibiotic use in chorioamnionitis-exposed newborns
MDedge Family Medicine
MDedge Daily News: Antibiotic resistance leads to ‘nightmare’ bacteria
MDedge Family Medicine
FDA advisory committee votes to recommend first once-daily aminoglycoside antibiotic
MDedge Family Medicine